Skip to main content

Table 2 Treatment-related adverse event: all events and grade ≥3 events

From: A phase II study on the role of gemcitabine plus romidepsin (GEMRO regimen) in the treatment of relapsed/refractory peripheral T-cell lymphoma patients

 

Any grade

Grades 3–4

N (%)

N (%)

Anemia

12 (60)

4 (20)

Neutropenia

11 (55)

10 (50)

Thrombocytopenia

16 (80)

12 (60)

Febrile neutropenia

2 (10)

0

Nausea and vomiting

10 (50)

0

Pyrexia

6 (30)

0

Transaminase increase

4 (20)

3 (15)